F10 and cancer: Notably, two high-grade randomized placebo-controlled trials assessed the efficacy and safety of primary thromboprophylaxis with prophylactic doses of 2.5 mg twice daily for up to 6 months of apixaban, a factor Xa inhibitor in the AVERT trial [104], and 10 mg once daily for up to 6 months of rivaroxaban, another factor Xa inhibitor in the CASSINI trial [105], in cancer patients with a Khorana score ≥ 2 undergoing chemotherapy.